Your questions answered Vol 2 - IM Private Clients
Discussion
I've been doing some sums and when the info comes back to where it should be I will be 7m better off, so I will cash in my chips and ride off into the sunset. Dietz method at its best :-)
( seriously should be a line on the account page stating that there's an error and it was being worked on once clients log on to their account)
( seriously should be a line on the account page stating that there's an error and it was being worked on once clients log on to their account)
superlightr said:
JulianPH said:
H
Yes, it is the Amazon share split causing a glitch in valuation display. Everyone will see this rectified with the next update.
next update as of today? doesnt look like its been updated yet?Yes, it is the Amazon share split causing a glitch in valuation display. Everyone will see this rectified with the next update.
I just put a lump sum in PHE last week and went to check that transactions had gone in properly. It was gut wrenching to see a 10% drop within a couple of days.
A nice announcement by Vertex on a very promising new drug. To put this into perspective, the FDA have only granted 'Breakthrough Therapy Designation' on 76 occasions in the past 6 years. Vertex already make a tonne of money from its Cystic Fibrosis treatments, so if successful it will light the after burners. We will know a lot more after 48 weeks trial data however we are in Phase 3 now and so far results are very promising.
Vertex Pharmaceuticals (PHT) announced that U.S. and European regulators issued key designations for its kidney disease candidate inaxaplin (VX-147) that would enable the company to speed up its regulatory work.
In the U.S., the FDA has granted its Breakthrough Therapy Designation for inaxaplin in APOL1-mediated focal segmental glomerulosclerosis (FSGS).
Meanwhile, the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation for the candidate in APOL1-mediated chronic kidney disease (AMKD).
FDA’s Breakthrough Therapy designation is aimed at speeding up the development and review of treatments targeted at serious or life-threatening conditions.
With the EMA's PRIME designation, the developers get early and proactive regulatory support for promising medications
Hi all
Adam is onto the Amazon stock split data feed with the office. We believe the issue is with the data feed we receive from out custodians, but are looking for the exact reason.
Essentially the stock is now 20X larger in number and 1/20th the price yet we are still reporting the ‘old’ shareholding (smaller quantity) at the new split price of $123 (rather than the previous $2,460 price).
This is causing everyone to see a 95% drop in valuation on this element of PHE (i.e. not the portfolio overall!), which does not actually exist.
Cheers
Julian
Adam is onto the Amazon stock split data feed with the office. We believe the issue is with the data feed we receive from out custodians, but are looking for the exact reason.
Essentially the stock is now 20X larger in number and 1/20th the price yet we are still reporting the ‘old’ shareholding (smaller quantity) at the new split price of $123 (rather than the previous $2,460 price).
This is causing everyone to see a 95% drop in valuation on this element of PHE (i.e. not the portfolio overall!), which does not actually exist.
Cheers
Julian
JulianPH said:
Hi all
Adam is onto the Amazon stock split data feed with the office. We believe the issue is with the data feed we receive from out custodians, but are looking for the exact reason.
Essentially the stock is now 20X larger in number and 1/20th the price yet we are still reporting the ‘old’ shareholding (smaller quantity) at the new split price of $123 (rather than the previous $2,460 price).
This is causing everyone to see a 95% drop in valuation on this element of PHE (i.e. not the portfolio overall!), which does not actually exist.
Cheers
Julian
Thank you for the quick response Julian, much appreciated Adam is onto the Amazon stock split data feed with the office. We believe the issue is with the data feed we receive from out custodians, but are looking for the exact reason.
Essentially the stock is now 20X larger in number and 1/20th the price yet we are still reporting the ‘old’ shareholding (smaller quantity) at the new split price of $123 (rather than the previous $2,460 price).
This is causing everyone to see a 95% drop in valuation on this element of PHE (i.e. not the portfolio overall!), which does not actually exist.
Cheers
Julian
leef44 said:
JulianPH said:
Hi all
Adam is onto the Amazon stock split data feed with the office. We believe the issue is with the data feed we receive from out custodians, but are looking for the exact reason.
Essentially the stock is now 20X larger in number and 1/20th the price yet we are still reporting the ‘old’ shareholding (smaller quantity) at the new split price of $123 (rather than the previous $2,460 price).
This is causing everyone to see a 95% drop in valuation on this element of PHE (i.e. not the portfolio overall!), which does not actually exist.
Cheers
Julian
Thank you for the quick response Julian, much appreciated Adam is onto the Amazon stock split data feed with the office. We believe the issue is with the data feed we receive from out custodians, but are looking for the exact reason.
Essentially the stock is now 20X larger in number and 1/20th the price yet we are still reporting the ‘old’ shareholding (smaller quantity) at the new split price of $123 (rather than the previous $2,460 price).
This is causing everyone to see a 95% drop in valuation on this element of PHE (i.e. not the portfolio overall!), which does not actually exist.
Cheers
Julian
Gassing Station | Finance | Top of Page | What's New | My Stuff